

STMN1 Antibody (C-Term)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP22150b

Product Information

Application WB, FC, E **Primary Accession** P16949

Other Accession O3T0C7, A9YWH3, O4R712, O6DUB7

Reactivity Human, Rat, Mouse

Predicted Bovine, Pig
Host Rabbit
Clonality polyclonal
Isotype Rabbit IgG
Clone Names RB56178
Calculated MW 17303

Additional Information

Gene ID 3925

Other Names Stathmin, Leukemia-associated phosphoprotein p18, Metablastin,

Oncoprotein 18, Op18, Phosphoprotein p19, pp19, Prosolin, Protein Pr22,

pp17, STMN1, C1orf215, LAP18, OP18

Target/Specificity This STMN1 antibody is generated from a rabbit immunized with a KLH

conjugated synthetic peptide between 106-140 amino acids from human

STMN1.

Dilution WB~~1:2000 FC~~1:25 E~~Use at an assay dependent concentration.

Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide.

This antibody is purified through a protein A column, followed by peptide

affinity purification.

Storage Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store

at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions STMN1 Antibody (C-Term) is for research use only and not for use in

diagnostic or therapeutic procedures.

Protein Information

Name STMN1

Synonyms C1orf215, LAP18, OP18

Function Involved in

Involved in the regulation of the microtubule (MT) filament system by destabilizing microtubules. Prevents assembly and promotes disassembly of microtubules. Phosphorylation at Ser-16 may be required for axon formation during neurogenesis. Involved in the control of the learned and innate fear (By similarity).

Cellular Location

Cytoplasm, cytoskeleton.

Tissue Location

Ubiquitous. Expression is strongest in fetal and adult brain, spinal cord, and cerebellum, followed by thymus, bone marrow, testis, and fetal liver. Expression is intermediate in colon, ovary, placenta, uterus, and trachea, and is readily detected at substantially lower levels in all other tissues examined. Lowest expression is found in adult liver. Present in much greater abundance in cells from patients with acute leukemia of different subtypes than in normal peripheral blood lymphocytes, non-leukemic proliferating lymphoid cells, bone marrow cells, or cells from patients with chronic lymphoid or myeloid leukemia.


Background

Involved in the regulation of the microtubule (MT) filament system by destabilizing microtubules. Prevents assembly and promotes disassembly of microtubules. Phosphorylation at Ser- 16 may be required for axon formation during neurogenesis. Involved in the control of the learned and innate fear (By similarity).

References


Zhu X.-X.,et al.J. Biol. Chem. 264:14556-14560(1989). Maucuer A.,et al.FEBS Lett. 264:275-278(1990). Melhem R.F.,et al.J. Biol. Chem. 266:17747-17753(1991). Hosoya H.,et al.Cell Struct. Funct. 21:237-243(1996). Ota T.,et al.Nat. Genet. 36:40-45(2004).

Images



Overlay histogram showing U-2 OS cells stained with AP22150b(green line). The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min. The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (AP22150b, 1:25 dilution) for 60 min at 37°C. The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(OH191631) at 1/200 dilution for 40 min at 37°C. Isotype control antibody (blue line) was rabbit IgG1 (1µg/1x10^6 cells) used under the same conditions. Acquisition of >10, 000 events was performed.

All lanes: Anti-STMN1 Antibody (C-Term) at 1:2000 dilution Lane 1: HT-29 whole cell lysate Lane 2: U-2OS whole cell lysate Lane 3: PC-12 whole cell lysate Lane 4: Hela whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size: 17 kDa Blocking/Dilution buffer: 5% NFDM/TBST.



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.